Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 6/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.43 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153894 | 0.86 | PDE4A (0.41) | HTR4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6153891 | 0.86 | PDE4A (0.41) | HTR4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3344888 | 0.83 | TOP2A (0.47) | HTR4MKNK1MKNK2UTS2RMAP3K5 | |
| SCHEMBL6153553 | 0.81 | PDE4B (0.44) | HTR4HTR3APDE4APDE4BPDE4C | |
| Trifluoroacetic Acid SCHEMBL6153987 | 0.80 | HTR4 (0.45) | HTR4HTR3ADRD4 | |
| SCHEMBL6154542 | 0.80 | HTR4 (0.58) | HTR4HTR3AACHEPDE4ADRD4 | |
| Hydrochloric Acid SCHEMBL6154062 | 0.79 | HTR4 (0.57) | HTR4HTR3AACHEPDE4ADRD4 | |
| SCHEMBL3876555 | 0.79 | GAA (0.53) | — | |
| SCHEMBL5372678 | 0.77 | MKNK1 (0.51) | MKNK1MKNK2MAP3K5TOP2AHSP90AB1 | |
| SCHEMBL12316430 | 0.77 | PDE4B (0.52) | TOP2APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440052-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | UNIV OF OULU (FI) | 2023-10-25 | — | — | EP | disclosed |
| US-20210346322-A1 | Compounds for use in the treatment of cancer | UNIVERSITY OF OULU (FI) | 2021-11-11 | — | — | US | disclosed |
| US-20190105289-A1 | Compounds for use in the treatment of cancer | UNIVERSITY OF OULU (FI) | 2019-04-11 | — | — | US | disclosed |
| EP-3440052-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | University Of Oulu (FI) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017174879-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITY OF OULU (FI) | 2017-10-12 | — | — | WO | disclosed |
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346322-A1 | Compounds for use in the treatment of cancer | PARP10, MACROD1, MACROD2 | HTR4 1829/4885MKNK1 3984/4885MKNK2 3770/4885 |
| US-20190105289-A1 | Compounds for use in the treatment of cancer | PARP10, MACROD1, MACROD2 | HTR4 1829/4885MKNK1 3984/4885MKNK2 3770/4885 |
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | HTR4 2642/4885MKNK1 2457/4885MKNK2 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.